Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases

BACKGROUND: Rare diseases are a global public health concern, affecting an estimated 350 million individuals. Only 5% of approximately 7000 known rare diseases have a treatment, and only about half have a patient advocacy organization. Biopharmaceutical companies face complex challenges in developin...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Susan, Bogard, Elizabeth, Boice, Nicole, Fernandez, Vivian, Field, Tessa, Gilstrap, Alan, Kahn, Susan R., Larkindale, Jane, Mathieson, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778794/
https://www.ncbi.nlm.nih.gov/pubmed/29357903
http://dx.doi.org/10.1186/s13023-018-0761-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778794/
https://www.ncbi.nlm.nih.gov/pubmed/29357903
http://dx.doi.org/10.1186/s13023-018-0761-2

Ejemplares similares